Emerging retatrutide, a twin -action treatment targeting equally GLP-1 and GIP receptors, is generating considerable excitement within the medical community. Preliminary clinical studies have shown substantial reductions in body weight and gains in metabolic markers for individuals with overweight. Researchers believe this novel approach may repres